Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01480622 | Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects | PHASE1 | COMPLETED | 14 | — | — | Dec 5, 2011 | Dec 30, 2011 | Jun 14, 2017 | 1 | China |
AUC(0-t) of single dose
AUC(0-τ) during steady state
| Arm | Type | Description |
|---|---|---|
| TDF tablets | EXPERIMENTAL | Tenofovir disoproxil fumarate tablets |
| Name | Type | Description |
|---|---|---|
| TDF tablets | DRUG | White, almond-shaped, film-coated tablets, one side with the markings "GILEAD" and "4331" |
Inclusion Criteria: * Healthy, as determined by a responsible and experienced physician * Male or female between 18 and 45 years of age * Body weight \>50 kg (110 lbs) for males or \>45 kg (100 lbs) for females, and body mass index (BMI) between 19.0 and 24.0 kg/m2 Exclusion Criteria: * Positive ...